Valeant (VRX) PT Bumped to $22 at Piper Jaffray; Keeps Lowest Rating

August 10, 2016 7:04 AM EDT
Get Alerts VRX Hot Sheet
Price: $22.10 +1.19%

Rating Summary:
    12 Buy, 11 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade VRX Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Piper Jaffray analyst David Amsellem bumped his price target on Valeant Pharmaceuticals (NYSE: VRX) to $22.00 (from $19.00) but maintained an Underweight rating following results and reaffirmed guidance, which the analyst said may be overly optimistic.

Amsellem commented, "Valeant reported 2Q16 non-GAAP diluted EPS of $1.40 on revenue of $2.42B, lighter than Street estimates. Management reiterated its 2016 guidance, which in our view may be overly optimistic. As such, we would not yet conclude that VRX is out of the woods with its creditors and certainly would not conclude that it is positioned for growth in the next 2-3 years at a minimum. Further, though VRX is looking for takers on assets that comprise over $2B in revenue and notably believes these divestitures could have an aggregate transaction value of around $8B, it is hard for us not to wonder if management and the Board is taking an overly sanguine view here (on what basis should we give VRX the benefit of the doubt?). We reiterate our Underweight rating and are raising our PT to $22 from $19, reflecting adjustments to our estimates."

The firm bumped FY 2016 EPS from $5.98 to $6.37 and FY 2017 EPS from $5.52 to $6.01.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $28.16 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment